Inclusion Criteria:

- Patients must have a diagnosis of neuroblastoma (ICD-O morphology 9500/3) verified by
histology and/or demonstration of clumps of tumor cells in bone marrow with elevated
urinary catecholamine metabolites

- Patients must meet one of the two following disease status criteria to enter on
study;

- Current or prior progressive disease (PD) by INRC criteria

- Either mixed response (MR) or no response (NR) by INRC criteria following
completion of minimum of 4 courses of induction therapy

- Patients meeting disease status criteria in either category A or B must also have at
least one of the following sites of disease present to enter on study:

- At least one tumor lesion on CT or MRI scan that is >= 20mm in at least one
dimension (spiral CT lesion must be >= 10mm in at least one dimension)

- MIBG scan with positive uptake at a minimum of one site

- Bone marrow disease documented by standard histology of bilateral bone marrow
aspirate and biopsy specimens

- Patients > 16 years of age: Karnofsky >= 50%; Patients =< 16 years of age: Lansky >=
50%; patients who are unable to walk because of paralysis, but who are up in a
wheelchair will be considered ambulatory for the purpose of assessing the performance
score; life expectancy must be >= 2 months for all patients

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- Chemotherapy and/or biologics: Must not have received treatment within 3 weeks
of entry onto this study (4 weeks if prior nitrosureas

- Radiation: At least 4 weeks since last dose of radiation therapy to at least one
lesion being used as criteria for study eligibility; only 2 weeks must elapse
since the last dose of radiation (small port) to a lesion not used for study
eligibility; at least 6 months must have elapsed since the last dose of prior
craniospinal XRT and radiation to >= 50% of the pelvis or TBI

- Stem Cell Transplant (SCT): >= 9 months must have elapsed since autologous
hematopoietic stem cell transplant (aHSCT)

- Prior MIBG therapy: At least 12 weeks must have elapsed since treatment with
therapeutic doses of MIBG

- Study specific limitations on prior therapy: patients who have a history of
allogeneic HSCT are not eligible

- Growth factor(s): At least 7 days since the last dose of any myeloid growth factor
was given

- Any patient considered for this protocol must meet the following criteria for minimum
number of autologous stem cells sufficient to rescue hematopoiesis; a combination of
products may be used to meet this requirement

- All stem cell products infused on this protocol must meet the following criteria for
tumor analysis: No tumor cells detectable by immunocytology OR for patients who had a
PBSC collection done previously and no immunocytological testing was done on the
product at the time of collection: This product may be used for infusion on this
study if the patient's bilateral bone marrow aspirate and biopsy specimens can be
shown to be tumor free by standard histology within 4 weeks of PBSC collection

- Glomerular filtration rate (GFR) using blood draw method or 12 hour urine collection
for creatinine clearance >= 100 ml/min/1.73 m^2

- Serum creatinine =< 1.5 x upper limit of normal for age

- Normal ejection fraction (>= 55%) documented by echocardiogram or radionuclide MUGA
evaluation OR normal fractional shortening (>= 27%) documented by echocardiogram

- Total bilirubin < 1.5 x upper limit of normal

- AST/ALT =< 3 x upper limit of normal

- Platelets >= 75,000/uL (transfusion independent)

- Hemoglobin >= 8 g/dl (transfusion allowed)

- Because evaluation of hematopoietic toxicity is essential to this study, the same
criteria will be applied to patients with tumor infiltration of the bone marrow

- Normal lung function as manifested by no dyspnea at rest and no oxygen requirement

Exclusion Criteria:

- No patients who are pregnant or lactating will be allowed to enter on study;
pregnancy tests must be obtained in females who are post-menarchal; males and females
of reproductive potential may not participate unless they have agreed to use an
effective method of contraception while receiving therapy

- Patients with active infections requiring intravenous antivirals, antibiotics, or
antifungals; patients on prolonged antifungal therapy are still eligible if they are
culture negative and biopsy negative in suspected residual radiographic lesions and
they meet other organ function criteria; patients who are known HIV seropositive with
stable disease and lack of major health problems who are not on anti-retroviral
therapy, may be eligible at the discretion of the Study Chair

- Prior treatment with Pyrazoloacridine (PZA)

- Prior history of allogeneic HSCT

- Neurologic Exclusions:

- Acute or chronic CNS disease

- History of seizures

- History of cerebral bleeding or stroke

- CNS parenchymal metastases as documented by head CT with contrast or head MRI
with gadolinium performed within 30 days of study entry. Patients with epidural
metastases causing mass effect on the brain are also excluded (skull metastases
are allowed provided they are not associated with intracranial disease
compressing or displacing the brain